TME Pharma N.V. (ALTME) AI Stock Analysis

• Market Cap: €10.69M
• Dividend Yield: N/A
• Average Volume (3M): 507.33K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.07
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: FR
• Employees: 12
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.03
• Shares Outstanding: 94,188,980
• 10 Day Avg. Volume: 628,806
• 30 Day Avg. Volume: 507,328
• PEG Ratio: <0.01
• Price to Book (P/B): 1.27
• Price to Sales (P/S): 107.95
• P/FCF Ratio: -0.44
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 45 Neutral
• Price Target: €0.00 ▼(-100.00% Downside)

The overall stock score is primarily impacted by the company's challenging financial performance, with persistent losses and negative cash flows. Technical analysis shows a neutral trend, while valuation metrics indicate unattractive investment prospects due to negative earnings and no dividend yield.

TME Pharma N.V. Business Overview & Revenue Model

Company Description

TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. Its Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, glioblastoma, and myeloma. It is also developing NOX-E36, which has completed Phase 1/2 clinical trial for the treatment of diabetic nephropathy. The company has a collaboration agreement with Merck Sharp & Dohme Corp. to study NOX-A12 combined with Keytruda and two different chemotherapy regimens as second-line therapy in patients with metastatic pancreatic cancer. The company was formerly known as NOXXON Pharma N.V. and changed its name to TME Pharma N.V. in July 2022. TME Pharma N.V. was founded in 1997 and is based in Berlin, Germany.

How the Company Makes Money

TME Pharma generates revenue primarily through collaborations and partnerships with pharmaceutical companies, as well as potential licensing agreements for its drug candidates. The company may also receive milestone payments tied to the successful development and commercialization of its products. Additionally, TME Pharma may benefit from grants or funding from governmental and non-governmental organizations that support cancer research and development initiatives. As the company advances its clinical trials and potentially brings products to market, it can expect to earn royalties from sales of its therapeutics.

TME Pharma N.V. Financial Statement Overview

Summary

TME Pharma N.V. is facing significant financial challenges with persistent losses and negative cash flows. Despite minor improvements in revenue and free cash flow growth, the company remains in a precarious financial position with high operational costs and negative equity in previous years. The low leverage is a positive aspect, but profitability and cash flow issues need addressing.

Income Statement

TME Pharma N.V. shows a challenging financial position with consistently negative margins across all metrics. The gross profit margin and net profit margin are significantly negative, indicating high costs relative to revenue. Although there is a slight revenue growth rate of 11.77% in the latest year, the EBIT and EBITDA margins remain deeply negative, reflecting ongoing operational losses.

Balance Sheet

The balance sheet reveals a low debt-to-equity ratio of 0.03, suggesting limited leverage, which is a positive aspect. However, the return on equity is negative, indicating that the company is not generating profit from its equity base. The equity ratio is not explicitly calculated, but the negative stockholders' equity in previous years highlights financial instability.

Cash Flow

Cash flow analysis shows a negative operating cash flow and free cash flow, although there is a notable improvement in free cash flow growth rate of 69.51%. The operating cash flow to net income ratio is negative, indicating cash flow challenges. The free cash flow to net income ratio is slightly above 1, suggesting that free cash flow is marginally covering net losses.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	19.00K	17.00K	0.00	33.00K	35.00
Gross Profit	-78.00K	-127.00K	-92.00K	-65.97K	-62.97K
EBITDA	-5.25M	-5.07M	-11.63M	-12.88M	-5.29M
Net Income	-5.72M	-6.74M	-15.13M	-14.45M	-10.40M
Balance Sheet
Total Assets	3.41M	2.49M	5.24M	9.77M	10.65M
Cash, Cash Equivalents and Short-Term Investments	3.25M	2.25M	4.63M	9.48M	10.30M
Total Debt	56.00K	1.17M	4.09M	2.44M	653.00K
Total Liabilities	1.79M	2.79M	6.51M	5.27M	2.96M
Stockholders Equity	1.61M	-294.00K	-1.27M	4.51M	7.71M
Cash Flow
Free Cash Flow	-4.65M	-5.65M	-12.16M	-12.39M	-5.26M
Operating Cash Flow	-4.63M	-5.63M	-12.14M	-12.38M	-5.22M
Investing Cash Flow	-21.00K	-19.00K	-21.00K	-14.00K	-39.00K
Financing Cash Flow	5.66M	3.27M	7.29M	11.50M	14.18M

TME Pharma N.V. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.10
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALTME, the sentiment is Negative. The current price of 0.1 is below the 20-day moving average (MA) of 0.10, below the 50-day MA of 0.10, and above the 200-day MA of 0.09, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 46.22 is Neutral, neither overbought nor oversold. The STOCH value of 44.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:ALTME.

TME Pharma N.V. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ALTME	45 Neutral	€10.69M	―	―	―	―	―